Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Current and emerging therapies in multiple sclerosis: a systematic review.
An assay to quantify species-specific anti-JC virus antibody levels in MS patients.
Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)
Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis.
Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort.
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15.
New EMA Advice to Reduce PML Risk With Natalizumab (Tysabri) in MS
Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor.
Up-regulated fractalkine (FKN) and its receptor CX3CR1 are involved in fructose-induced neuroinflammation: Suppression by curcumin.
JCV granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
[Non-medicinal treatments of spasticity in multiple sclerosis].
A new therapeutic target for the treatment of multiple sclerosis.
CD226 Gly307Ser association with multiple autoimmune diseases: A meta-analysis.
Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).
The role of IFNβ in the treatment of MSand EAE - In the perspective of inflammasomes.
Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.
1,25-Dihydroxyvitamin D3 Suppresses TLR8 Expression and TLR8-Mediated Inflammatory Responses in Monocytes In Vitro and Experimental Autoimmune Encephalomyelitis In Vivo.
Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
Myelin oligodendrocyte glycoprotein induces aquaporin-4 autoantibodies in mouse experimental autoimmune encephalomyelitis.
Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders.
Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.
Characterisation of uveitis in association with multiple sclerosis.
Autologous hematopoietic stem cell transplantation for multiple sclerosis - if confused or hesitant, remember: 'Treat with standard immune suppressive drugs and if no inflammation, no response'.
Pages
« first
‹ previous
…
270
271
272
273
274
275
276
277
278
…
next ›
last »